Evidence map›Paper›PMID 25930983›Full record

ArticleCancer2015

Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study.

James D Murphy, Grace L Ma, Joel M Baumgartner, Lisa Madlensky, Adam M Burgoyne, Chih-Min Tang, Maria Elena Martinez, Jason K Sicklick

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. 2023 GEIS Guidelines for gastrointestinal stromal tumors.Therapeutic advances in medical oncology · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

James D MurphyDepartment of Radiation and Applied Sciences, Moores Cancer Center, University of California San Diego, La Jolla, California.
Grace L MaDivision of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California San Diego, La Jolla, California.
Joel M BaumgartnerDivision of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California San Diego, La Jolla, California.
Lisa MadlenskyDepartment of Family and Preventive Medicine, Moores Cancer Center, University of California San Diego, La Jolla, California.
Adam M BurgoyneDivision of Medical Oncology, Department of Internal Medicine, Moores Cancer Center, University of California San Diego, La Jolla, California.
Chih-Min TangDivision of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California San Diego, La Jolla, California.
Maria Elena MartinezDepartment of Family and Preventive Medicine, Moores Cancer Center, University of California San Diego, La Jolla, California.
Jason K SicklickDivision of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California San Diego, La Jolla, California.

Funding

Blood Cells in Hemostasis and ThrombosisT32HL086344 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GINSBERG, MARK HOWARD · 2008 to 2023
$4.4M
Novel Allosteric Kinase Inhibitors Target Imatinib-Resistant GISTK08CA168999 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SICKLICK, JASON KEITH · 2014 to 2018
$888k
San Diego Clinical and Translational Research InstituteKL2RR031978 · NCRR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S · 2010 to 2011
$615k
NCI NIH HHS K08 CA168999NCRR NIH HHS KL2 RR031978NCRR NIH HHS KL2RR031978NHLBI NIH HHS T32 HL086344
6 · The paper itself

Abstract

backgroundMost gastrointestinal stromal tumors (GISTs) are considered nonhereditary or sporadic. However, single-institution studies suggest that GIST patients develop additional malignancies at increased frequencies. It was hypothesized that greater insight could be gained into possible associations between GISTs and other malignancies with a national cancer database inquiry.

methodsPatients diagnosed with GISTs (2001-2011) in the Surveillance, Epidemiology, and End Results database were included. Standardized prevalence ratios (SPRs) and standardized incidence ratios (SIRs) were used to quantify cancer risks incurred by GIST patients before and after GIST diagnoses, respectively, in comparison with the general US population.

resultsThere were 6112 GIST patients, and 1047 (17.1%) had additional cancers. There were significant increases in overall cancer rates: 44% (SPR, 1.44) before the GIST diagnosis and 66% (SIR, 1.66) after the GIST diagnosis. Malignancies with significantly increased occurrence both before and after diagnoses included other sarcomas (SPR, 5.24; SIR, 4.02), neuroendocrine-carcinoid tumors (SPR, 3.56; SIR, 4.79), non-Hodgkin lymphoma (SPR, 1.69; SIR, 1.76), and colorectal adenocarcinoma (SPR, 1.51; SIR, 2.16). Esophageal adenocarcinoma (SPR, 12.0), bladder adenocarcinoma (SPR, 7.51), melanoma (SPR, 1.46), and prostate adenocarcinoma (SPR, 1.20) were significantly more common only before the GIST diagnosis. Ovarian carcinoma (SIR, 8.72), small intestine adenocarcinoma (SIR, 5.89), papillary thyroid cancer (SIR, 5.16), renal cell carcinoma (SIR, 4.46), hepatobiliary adenocarcinoma (SIR, 3.10), gastric adenocarcinoma (SIR, 2.70), pancreatic adenocarcinoma (SIR, 2.03), uterine adenocarcinoma (SIR, 1.96), non-small cell lung cancer (SIR, 1.74), and transitional cell carcinoma of the bladder (SIR, 1.65) were significantly more common only after the GIST diagnosis.

conclusionsThis is the first population-based study to characterize the associations and temporal relations between GISTs and other cancers by both site and histological type. These associations may carry important clinical implications for future cancer screening and treatment strategies.

Indexed as

AdultAgedAged, 80 and overFemaleGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHumansIncidenceMaleMiddle AgedNeoplasms, Second PrimaryRisk FactorsYoung Adultgastrointestinal stromal tumor (GIST)multiple primary neoplasmsecond primary neoplasmsSurveillance, Epidemiology, and End Results (SEER)synchronous neoplasms

Identifiers

PMID25930983
PMCPMC4545693

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.